Bulbar and pseudobulbar palsy complicating therapy with high‐dose cytosine arabinoside in children with leukemia
- 1 January 1991
- journal article
- case report
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 19 (2) , 122-125
- https://doi.org/10.1002/mpo.2950190210
Abstract
Three of 38 children given high‐dose cytosine arabinoside therapy developed a previously undescribed complication. Neurological problems are a frequent occurrence in patients given this therapy, particularly cerebellar ataxia, but the development of bulbar and pseudobulbar palsy has not been reported. In two of these cases, it was sufficiently marked for the course of treatment to be curtailed and occurred at a relatively low cumulative dose of the drug. Neurotoxicity can occur at any time using high‐dose cytosine therapy.Keywords
This publication has 16 references indexed in Scilit:
- High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.Journal of Clinical Oncology, 1987
- Neurotoxicity associated with systemic high-dose cytosine arabinoside.Journal of Clinical Oncology, 1986
- Central nervous system toxicity with high‐dose Ara‐CNeurology, 1985
- Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.Journal of Clinical Oncology, 1985
- Central nervous system toxicity of high‐dose cytosine arabinosideMedical and Pediatric Oncology, 1983
- Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: intensivierte Reinduktionstherapie für Patientengruppen mit unterschiedlichem RezidivrisikoKlinische Padiatrie, 1982
- Letter: neuropathy due to cytosine arabinoside.BMJ, 1974
- Letter: Neurotoxicity of intrathecal chemotherapy for leukaemia.BMJ, 1973